Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00109044 · ClinicalTrials.gov registry record · Phase 3
Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder
A Phase 3 study of Major Depressive Disorder, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 540
- Enrollment target
- 18
- Study locations
NCT00109044: Completed Phase 3 study of Major Depressive Disorder, sponsored by Forest Laboratories.
NCT00109044 is a Phase 3 study of Major Depressive Disorder that has completed, run by Forest Laboratories. The registered enrollment target is 540 participants, above the 375-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (44% higher). The trial reports 18 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00109044, a Phase 3 study of Major Depressive Disorder, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 540 participants
- Enrollment target
- 18
- Study locations
Study Summary
Escitalopram is the S-enantiomer of citalopram. Both escitalopram and citalopram are selective serotonin reuptake inhibitors (SSRIs) and are used to treat depression in adults. This study is designed to evaluate the efficacy and safety of a fixed-dose escitalopram combination relative to its component monotherapies and to placebo in patients with major depressive disorder.
Conditions Studied
Interventions
- DRUG Escitalopram
Study Locations (18)
Colorado
- Alpine Clinical Research - Boulder
- Radiant Research, Inc. - Denver
Illinois
- Cunningham Clinical Research, LLC - Edwardsville
- Midwest Center for Neurobiological Medicine - Oakbrook Terrace
New Jersey
- CNS Research Institute - Clementon
- Center for Emotional Fitness - Moorestown
Texas
- Claghorn-Lesem Research Clinic - Bellaire
- Croft Group Research Center - San Antonio
Washington
- Northwest Clinical Research Center - Bellevue
- Summit Research Network (Seattle), LLC - Seattle
Arizona
- Southwest Health, Ltd - Phoenix
Florida
- Clinical Neuroscience Solutions, Inc. - Orlando
Maryland
- Capital Clinical Research Associates - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 540 participants |
| Start Date | 2005-03 |
| Est. Completion | 2006-05 |
| Phase | Phase 3 |
What the finished NCT00109044 record still lists
NCT00109044 is an interventional study that assigns participants to a tested intervention. The registered 540 participants enrollment target is mid-sized for trials with a published cap, above the 375-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (44% higher).
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Escitalopram is the first listed.
NCT00109044 lists 18 locations in 13 states (Colorado, Illinois, New Jersey).
Frequently Asked Questions
What is clinical trial NCT00109044 about?
NCT00109044 is a clinical study titled "Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder". Escitalopram is the S-enantiomer of citalopram. Both escitalopram and citalopram are selective serotonin reuptake inhibitors (SSRIs) and are used to treat depression in adults. This study is designed to evaluate the efficacy and safety of a fixed-dose escitalopram combination relative to its compone...
What is the current status of trial NCT00109044?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 540 participants. The study started on 2005-03. Estimated completion is 2006-05.
What conditions does trial NCT00109044 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT00109044?
The interventions under investigation include: Escitalopram (DRUG).
Who is sponsoring clinical trial NCT00109044?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00109044 being conducted?
This trial has 18 study locations across Arizona, Colorado, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00109044's enrollment target sits among peer trials
540 28th of 282 higher than 255 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
Study to Assess the Safety and Effectiveness of NMRA-335140-501
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
RECRUITING · Phase 3
-
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
RECRUITING · Phase 3
-
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04557462 · 540 participants · Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- NCT04956640 · 540 participants · Phase 1
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
- NCT05429892 · 540 participants · NA
FRESH Delivers: An Innovative Approach to Reducing Tobacco Use Among Rural Smokers
- NCT05549297 · 540 participants · Phase 3
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia